US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

16 deals · US$3.8bndisclosed · Pharma · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Dec 2025 Apimeds Pharmaceuticals US ––ConvertibleCompleted10.9Pharma+1 Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager)
Jan 2026 Aktis Oncology ––IPOListed317.7Biotech+2 Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager)
Feb 2026 Perspective Therapeutics ––Follow-on offeringAnnounced175.0Radiopharmaceuticals+2 Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager)
Feb 2026 Veradermics ––IPOAnnounced256.3Dermatology+2 Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager)
Feb 2026 Agomab Therapeutics NV ––IPOAnnounced200.0Biotech+2 Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager)
Feb 2026 SpyGlass Pharma ––IPOAnnounced150.0Ophthalmology+1 Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager)
Apr 2026 Ionetix Corp. ––PlacementCompleted30.0Radiopharmaceuticals+1
Apr 2026 Avalyn Pharma ––IPOListed300.0Biotech+2 Goodwin (issuer)Morgan Stanley (lead manager)Jefferies (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Davis Polk (lead manager)
Apr 2026 Hemab Therapeutics Holdings ––IPOAnnounced301.5Biotech+1 WilmerHale (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager)
Apr 2026 Seaport Therapeutics ––IPOAnnounced254.9Biotech+1 Goodwin (issuer)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager)
May 2026 Quince Therapeutics ––PlacementAnnounced115.0Biotech+2 EvercoreCantor FitzgeraldLifeSci Capital (lead manager)Gibson Dunn (lead manager)
May 2026 Mentari Therapeutics ––PlacementAnnounced290.0Biotech+1 Gibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Guggenheim Securities (lead manager)Wedbush Securities (lead manager)
May 2026 Optimi Health Corp. ––Follow-on offeringAnnounced15.0Biotech+2 Norton Rose Fulbright (issuer)Joseph Gunnar & Co. (lead manager)Cozen O'Connor (lead manager)
Jul 2026 BridgeBio Pharma ––PlacementAnnounced1,000.0Biotech+1 EvercoreSullivan & CromwellMintzGibson DunnLatham & Watkins (issuer)
Jul 2026 Inovio Pharmaceuticals ––Follow-on offeringCompleted–Biotech+1 Piper Sandler (issuer)
Aug 2026 Latigo Biotherapeutics ––IPOListed345.6Biotech+2 Cooley (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)Latham & Watkins (lead manager)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built